JAZZ News and Press, Jazz Pharmaceuticals plc From 10/20/20

NLS Pharmaceutics has filed to raise $20 million in a U.S. IPO. The firm is advancing treatments for narcolepsy and ADHD. NLSP is thinly capitalized and has made no apparent progress on beginning trials for its lead candidate, so I'll pass on the IPO. For further details see...

Jazz Pharmaceuticals announces topline data from Phase 3 Xywav trial. MacroGenics reports positive data for flotetuzumab immunotherapy. Merck provides updated positive data for Keytruda in lung cancer. For further details see: Jazz Announces Topline Data, And Other News:...

Jazz Pharmaceuticals (JAZZ) has announced the publication of Phase 3 study results of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime sleepiness ((EDS)) in adults with narcolepsy. The results were published in SLEEP,...

Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy Xywav demonstrated highly statistically significant differe...

Jazz Pharmaceuticals (JAZZ) will host a virtual investor event on Monday, October 26, at 4:30 pm ET to discuss the commercial launch of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, approved in the U.S. in July for cataplexy (excessive daytime sleepiness) in patien...

Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update PR Newswire DUBLIN, Oct. 19, 2020 DUBLIN , Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, October 2...

Jazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020 PR Newswire DUBLIN, Oct. 19, 2020 DUBLIN , Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 third qua...

New Data for Zepzelca™ (lurbinectedin) to be Presented at IASLC 2020 North America Conference on Lung Cancer Updated second-line SCLC analysis from Phase 2 basket trial previously published in The Lancet Oncology among study results to be presented PR Newswire DUB...

Despite the groundbreaking announcements in the recent past, JAZZ’s YTD performance lags the broader market. Though recent product launches could hurt the margins, they warrant an upgrade to revenue outlook in light of historical trends. Our conservative estimates for the y...

Praxis Precision Medicines has filed proposed terms for its U.S. IPO. The firm is developing treatments for various central nervous system and other disorders. PRAX has demonstrated positive early efficacy results, so for life science investors, the IPO is worth a close look. ...